NOX — Noxopharm Share Price
0.000.00%
Last trade - 00:00- AU$27.18m
- AU$28.10m
- AU$2.83m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 39.39 | ||
| Price to Tang. Book | 39.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -756.41% | ||
| Return on Equity | -157.93% | ||
| Operating Margin | -190.08% | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 5.75 | 5.45 | 6.07 | 2.41 | 2.83 | n/a | n/a | -19.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Noxopharm Limited is a clinical-stage biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA drug enhancement, and oncology). Chroma is a technology platform, which is focused on development of drug candidates based on a scaffold structure known as functionalized benzopyrans. Sofra technology platform comprises a novel class of drugs targeting inflammatory and autoimmune diseases based on oligonucleotides, the building blocks of DNA, with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-SKN is a novel drug candidate for autoimmune diseases that targets an inflammatory sensor called TLR7.
Directors
- Frederick Bart NEC (66)
- Graham Kelly NED (70)
- Peter Marks NVC (65)
- Shawn Van Boheemen CFO
- Jeanette Bell COO
- Alexander Hunter OTH
- David Franks SEC
- Boris Patkin NED
- Last Annual
- June 30th, 2025
- Last Interim
- June 30th, 2025
- Incorporated
- October 27th, 2015
- Public Since
- August 9th, 2016
- No. of Shareholders
- 3,227
- No. of Employees
- 1,000
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 292,237,950
- Address
- Suite 71, 159 Ridgecrop Drive, CASTLE HILL, 2154
- Web
- https://www.noxopharm.com/
- Phone
- +61 291442223
- Auditors
- William Buck Audit (Vic) Pty Ltd
Upcoming Events for NOX
Similar to NOX
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Noxopharm share price?
As of Today at 22:23 UTC, shares in Noxopharm are trading at AU$0.09. This share price information is delayed by 15 minutes.
How has the Noxopharm share price performed this year?
Shares in Noxopharm last closed at AU$0.09 and the price had moved by -22.5% over the past 365 days. In terms of relative price strength the Noxopharm share price has underperformed the ASX All Ordinaries Index by -28.08% over the past year.
What are the analyst and broker recommendations for Noxopharm?
The overall consensus recommendation for Noxopharm is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Noxopharm dividend yield?
Noxopharm does not currently pay a dividend.
Does Noxopharm pay a dividend?
Noxopharm does not currently pay a dividend.
When does Noxopharm next pay dividends?
Noxopharm does not currently pay a dividend.
How do I buy Noxopharm shares?
To buy shares in Noxopharm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Noxopharm?
As of the previous close price of AU$0.09, shares in Noxopharm had a market capitalisation of AU$27.18m.
Where are Noxopharm shares listed?
Here are the trading details for Noxopharm:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: NOX
What kind of share is Noxopharm?
Based on an overall assessment of its quality, value and momentum Noxopharm is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Noxopharm share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Noxopharm share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Noxopharm. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -5.65%.
As of the last closing price of AU$0.09, shares in Noxopharm were trading +10.29% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Noxopharm PE Ratio?
The Noxopharm PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Noxopharm?
Noxopharm's management team is headed by:
- Frederick Bart - NEC
- Graham Kelly - NED
- Peter Marks - NVC
- Shawn Van Boheemen - CFO
- Jeanette Bell - COO
- Alexander Hunter - OTH
- David Franks - SEC
- Boris Patkin - NED